Table 1.

Differences between Bevacizumab and Ranibizumab (per approved labels)

Characteristic	Bevacizumab	Ranibizumab
Structure	Recombinant full monoclonal antibody which is humanized	Recombinant fragment (Fab) monoclonal antibody which is humanized - IgG1 kappa isotype
Source	Produced in Chinese Hamster Ovary cells	Produced by an Escherichia coli expression system
Molecular Weight	149 kD	48 kD
Formulation	Trehalose dihydrate; sodium phosphate; polysorbate 20; water for injection	α,α-trehalose dehydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injection
Route of administration	Intravenous	Intravitreal
Formulation and strength	25 mg per mL100 mg in 4 mL and 400 mg in 16 mL in vial	10 mg per mL and 6 mg per mL0.3 mg in 0.05 mL and 0.5 mg in 0.05 mL in vial and prefilled syringe
Dosage	5-15 mg per kg	0.3 mg or 0.5 mg
Method of administration	Diluted in saline and administered intravenously	Injected intravitreally, no dilution required
Development plan	Developed only for systemic administration and nonclinical and clinical development tuned for that	Developed only for eye administration and nonclinical and clinical development tuned for that
Nonclinical studies	No testing done for eye toxicity intravitreally. Systemic studies done in animals	Tested for eye toxicity intravitreally
Developmental clinical studies	Not tested for effects in eye intravitreally. Systemic studies done in cancers	Tested for effects in the eye intravitreally
Therapeutic indications	Different cancer diseases	Different eye diseases

Lucentis Summary of Product Characteristics[1] and Avastin Summary of Product Characteristics[10]